Publication Name	World Journal of Psychiatry
Manuscript ID	54597
Country	United States

Received	2020-02-13 14:27
Peer-Review Started	2020-02-13 14:28
To Make the First Decision
Return for Revision	2020-04-03 17:14
Revised	2020-05-25 01:06
Second Decision	2020-06-08 09:09
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-06-10 20:04
Articles in Press	2020-06-10 20:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-07-10 01:52
Publish the Manuscript Online	2020-07-17 03:31

ISSN	2220-3206 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Psychiatry
Manuscript Type	Systematic Reviews
Article Title	Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
Manuscript Source	Invited Manuscript
All Author List	Shilpa Srinivasan, Rajesh R Tampi, Kripa Balaram and Arushi Kapoor
Funding Agency and Grant Number
Corresponding Author	Shilpa Srinivasan, MD, Doctor, Professor, Department of Neuropsychiatry and Behavioral Science, Palmetto Health USC Medical Group, University of South Carolina School of Medicine, 3555 Harden Street Extension, Suite 301, Columbia, SC 29203, United States. shilpa.srinivasan@uscmed.sc.edu
Key Words	Pimavanserin; Alzheimer’s disease; Psychosis; Psychotic disorders; Antipsychotic agents;
Core Tip	This systematic review was conducted to evaluate the evidence from randomized controlled clinical trials of pimavanserin for the treatment of psychosis in individuals with Alzheimer’s disease (AD). Behavioral disturbances including psychosis are prevalent in AD, and have a significant impact on management and outcomes. There are currently no United States Food and Drug Administration approved medications for the management of behavioral disturbance in AD. Based on the findings of our systematic review, pimavanserin, a novel atypical antipsychotic, may be a new pharmacologic consideration for treating psychosis in individuals with AD.
Publish Date	2020-07-17 03:31
Citation	Srinivasan S, Tampi RR, Balaram K, Kapoor A. Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review. World J Psychiatr 2020; 10(7): 162-174
URL	https://www.wjgnet.com/2220-3206/full/v10/i7/162.htm
DOI	https://dx.doi.org/10.5498/wjp.v10.i7.162

Full Article (PDF)	WJP-10-162.pdf
Full Article (Word)	WJP-10-162.docx
Manuscript File	54597-Review.docx
Answering Reviewers	54597-Answering reviewers.pdf
Audio Core Tip	54597-Audio core tip.m4a
Biostatistics Review Certificate	54597-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	54597-Conflict-of-interest statement.pdf
Copyright License Agreement	54597-Copyright license agreement.pdf
Supplementary Material	54597-Supplementary material.pdf
Peer-review Report	54597-Peer-review(s).pdf
Scientific Misconduct Check	54597-CrossCheck.png
Scientific Misconduct Check	54597-Bing-Yan JP-2.png
Scientific Misconduct Check	54597-Scientific misconduct check.pdf
Scientific Editor Work List	54597-Scientific editor work list.pdf